JP5836963B2 - キナゾリン化合物 - Google Patents

キナゾリン化合物 Download PDF

Info

Publication number
JP5836963B2
JP5836963B2 JP2012537925A JP2012537925A JP5836963B2 JP 5836963 B2 JP5836963 B2 JP 5836963B2 JP 2012537925 A JP2012537925 A JP 2012537925A JP 2012537925 A JP2012537925 A JP 2012537925A JP 5836963 B2 JP5836963 B2 JP 5836963B2
Authority
JP
Japan
Prior art keywords
amino
methyl
quinazolinyl
methyloxy
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012537925A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013510155A (ja
JP2013510155A5 (enExample
Inventor
ララ、エス．カランダー
ブライアン、グリフィン、ローホーン
ジョアンヌ、フィルプ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of JP2013510155A publication Critical patent/JP2013510155A/ja
Publication of JP2013510155A5 publication Critical patent/JP2013510155A5/ja
Application granted granted Critical
Publication of JP5836963B2 publication Critical patent/JP5836963B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2012537925A 2009-11-03 2010-11-01 キナゾリン化合物 Expired - Fee Related JP5836963B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25764609P 2009-11-03 2009-11-03
US61/257,646 2009-11-03
PCT/US2010/054927 WO2011056740A1 (en) 2009-11-03 2010-11-01 Quinazoline compounds

Publications (3)

Publication Number Publication Date
JP2013510155A JP2013510155A (ja) 2013-03-21
JP2013510155A5 JP2013510155A5 (enExample) 2013-12-19
JP5836963B2 true JP5836963B2 (ja) 2015-12-24

Family

ID=43970282

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012537925A Expired - Fee Related JP5836963B2 (ja) 2009-11-03 2010-11-01 キナゾリン化合物

Country Status (13)

Country Link
US (1) US8859571B2 (enExample)
EP (1) EP2501233B1 (enExample)
JP (1) JP5836963B2 (enExample)
KR (1) KR101736521B1 (enExample)
CN (1) CN102711474B (enExample)
AU (1) AU2010315361B2 (enExample)
BR (1) BR112012010524A2 (enExample)
CA (1) CA2779989A1 (enExample)
EA (1) EA021439B1 (enExample)
ES (1) ES2523465T3 (enExample)
IL (1) IL219504A (enExample)
MX (1) MX2012005155A (enExample)
WO (1) WO2011056740A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2398797B1 (en) * 2009-02-17 2013-11-06 Boehringer Ingelheim International GmbH Pyrimido[5,4-d]pyrimidine derivatives for the inhibition of tyrosine kinases
CN103159685A (zh) * 2013-04-11 2013-06-19 苏州立新制药有限公司 4-氯-6，7-二(2-甲氧基乙氧基)喹唑啉的制备方法
AU2014353006B2 (en) * 2013-11-20 2019-04-04 Signalchem Life Sciences Corp. Quinazoline derivatives as TAM family kinase inhibitors
WO2015099916A1 (en) 2013-12-26 2015-07-02 Exxonmobil Research And Engineering Company Synthesis of zsm-48 crystals
KR20240017986A (ko) * 2017-09-26 2024-02-08 더 리전트 오브 더 유니버시티 오브 캘리포니아 암 치료를 위한 조성물 및 방법
EP4031247A1 (en) 2019-09-16 2022-07-27 Novartis AG Bifunctional degraders and their methods of use
CA3233057A1 (en) 2021-09-23 2023-03-30 Erasca, Inc. Egfr inhibitor polymorph forms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases

Also Published As

Publication number Publication date
KR101736521B1 (ko) 2017-05-16
ES2523465T3 (es) 2014-11-26
EA201290243A1 (ru) 2012-12-28
JP2013510155A (ja) 2013-03-21
IL219504A (en) 2016-09-29
CA2779989A1 (en) 2011-05-12
CN102711474B (zh) 2014-09-10
CN102711474A (zh) 2012-10-03
IL219504A0 (en) 2012-06-28
US8859571B2 (en) 2014-10-14
AU2010315361A1 (en) 2012-05-24
WO2011056740A1 (en) 2011-05-12
EP2501233A1 (en) 2012-09-26
EP2501233A4 (en) 2013-06-19
KR20120112441A (ko) 2012-10-11
MX2012005155A (es) 2012-08-31
EA021439B1 (ru) 2015-06-30
EP2501233B1 (en) 2014-09-24
AU2010315361B2 (en) 2014-06-12
BR112012010524A2 (pt) 2017-12-12
US20120220588A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
CN114605400B (zh) 杂芳基衍生物、其制备方法、及含其作为有效成分的药物组合物
JP4440642B2 (ja) ピリミジンＡ２ｂ選択的アンタゴニスト化合物、それらの合成、及び使用
CN103987700B (zh) 4-喹唑啉胺类衍生物及其用途
JP6035423B2 (ja) 新規な縮合ピリミジン化合物又はその塩
KR101424847B1 (ko) 피리미딘 유도체
CN102918029B (zh) 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
TWI603971B (zh) Novel quinoline substituted compounds
JP2013517273A (ja) 化合物および方法
WO2017038838A1 (ja) 新規なピラゾロ［３，４－ｄ］ピリミジン化合物又はその塩
JP2008514643A (ja) 新規ピペリジニルアミノ−チエノ［２，３−ｄ］ピリミジン化合物
WO2016011979A1 (zh) 2，4-二取代7H-吡咯并[2，3-d]嘧啶衍生物、其制法与医药上的用途
KR101736521B1 (ko) 퀴나졸린 화합물
JP6250674B2 (ja) Ｎ型カルシウムチャネル遮断剤としてのピロロピラゾール
JP2019519534A (ja) 五員複素環［３，４−ｄ］ピリダジノン系化合物、その製造方法、医薬組成物及び応用
CN107235906A (zh) 一组吡唑酰胺类衍生物及其应用
KR20230163335A (ko) 헤테로아릴 유도체 화합물 및 이의 용도
CN110372666A (zh) 喹唑啉类化合物作为egfr三突变抑制剂及其应用
TW201504227A (zh) 環狀胺基甲基嘧啶衍生物
US20120157482A1 (en) Compounds and methods
TWI867047B (zh) 雜芳基衍生物、其製備方法、及含彼作為活性成份之藥學組成物
WO2011088031A1 (en) Compounds and methods
CN113943251B (zh) 双环庚烯基氨基取代的氮杂芳环类化合物及其医药用途
AU2014269229A1 (en) Bicyclic derivative containing pyrimidine ring, and preparation method therefor
HK40074494A (en) Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
CN118221696A (zh) 含有n-甲基哌嗪结构的嘧啶杂环类化合物及其制备方法和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131028

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20141217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150406

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151006

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151104

R150 Certificate of patent or registration of utility model

Ref document number: 5836963

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees